Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma.

@article{Tefferi1994PhaseIS,
  title={Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma.},
  author={Ayalew Tefferi and Thomas E Witzig and Joel M. Reid and C Y Li and Matthew Ames},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1994},
  volume={12 3},
  pages={569-74}
}
PURPOSE We conducted a dose-escalation study of 2-chlorodeoxyadenosine (2-CdA) added to a standard fixed dose of chlorambucil to evaluate the toxicity of the combined regimen in patients with chronic lymphocytic leukemia (CLL) and low-grade lymphoma. PATIENTS AND METHODS A total of 15 adults with relapsed or refractory CLL or low-grade lymphoma were to receive chlorambucil orally (30 mg/m2) every 2 weeks. Also, groups of three patients were to receive escalating doses of continuous… CONTINUE READING